A Study of Disease Progression and Anti-HIV Treatments

Completed · Phase 2

Conditions studied: HIV Infections

In brief

To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.

Key facts

Study ID
NCT00001068
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
210
Expected to finish
1998-10-01
Last updated by the study team
2021-11-04

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.